These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 12755009

  • 1. [Renin-angiotensin system as a potential target for the treatment with heart failure: ACE inhibitors, angiotensin-II receptor blockers and aldosterone antagonists].
    Sanada S, Kitakaze M.
    Nihon Rinsho; 2003 May; 61(5):821-6. PubMed ID: 12755009
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ.
    Circulation; 2004 Nov 16; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract] [Full Text] [Related]

  • 4. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Nov 16; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T, Takeshita A.
    Nihon Rinsho; 2003 May 16; 61(5):801-6. PubMed ID: 12755006
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A, Divchev D, Luchtefeld M, Schieffer B.
    Minerva Cardioangiol; 2009 Dec 16; 57(6):773-85. PubMed ID: 19942847
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 16; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 8. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
    Carson PE.
    Am Heart J; 2000 Sep 16; 140(3):361-6. PubMed ID: 10966531
    [Abstract] [Full Text] [Related]

  • 9. The renin-angiotensin-aldosterone system and heart failure.
    Sayer G, Bhat G.
    Cardiol Clin; 2014 Feb 16; 32(1):21-32, vii. PubMed ID: 24286576
    [Abstract] [Full Text] [Related]

  • 10. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 16; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 11. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
    Azizi M.
    Rev Prat; 2004 Jun 15; 54(11):1167-74. PubMed ID: 15496022
    [Abstract] [Full Text] [Related]

  • 12. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S.
    Acta Med Indones; 2008 Jan 15; 40(1):34-7. PubMed ID: 19054878
    [Abstract] [Full Text] [Related]

  • 13. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ, Smith SM, Choksi R.
    Expert Rev Cardiovasc Ther; 2009 Nov 15; 7(11):1373-84. PubMed ID: 19900020
    [Abstract] [Full Text] [Related]

  • 14. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M, Lamas GA.
    Expert Rev Cardiovasc Ther; 2004 Nov 15; 2(6):891-902. PubMed ID: 15500434
    [Abstract] [Full Text] [Related]

  • 15. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH, Voors AA.
    Int J Cardiol; 2006 Jan 26; 106(3):367-72. PubMed ID: 16337046
    [Abstract] [Full Text] [Related]

  • 16. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 26; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 17. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun 26; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 18. [Inhibition of renin-angiotensin-aldosterone system: what evidence?].
    Mota T.
    Rev Port Cardiol; 2001 Mar 26; 20 Suppl 3():13-5. PubMed ID: 11409069
    [Abstract] [Full Text] [Related]

  • 19. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 26; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 20. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA, Wendt C, Saborowski F.
    Fiziol Cheloveka; 2005 Jan 26; 31(6):97-105. PubMed ID: 16366159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.